ANSYS on Capitol Hill: Simulation is An Important Component to Solve the Global Healthcare Issue

Over the last six months, significant progress has been made to foster Transatlantic collaboration in the area of in silico medicine. I say significant because the collaboration is now being fostered beyond the technical level. It is happening at the regulatory and policy levels. On October 11th, 2016, the U.S. FDA spoke at the European Parliament as part of an inauguration event for the Avicenna Alliance, the association of predictive medicine, of which ANSYS is a founding member. Last week, the collaboration was reciprocated. The Avicenna Alliance was invited by the FDA and by the staff of Senator T. Cochran to discuss the role of in silico medicine in both a technical context at the 2017 BMES conference and also at the policy level on Capitol Hill. Continue reading